The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

CA16020854

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: c746efb0-6516-407e-bad0-a2cc5b62fb0b

HGVS expressions

NM_000277.1:c.755G>C
NM_000277.2:c.755G>C
NM_001354304.1:c.755G>C
NM_000277.3:c.755G>C
NM_001354304.2:c.755G>C
ENST00000307000.7:c.740G>C
ENST00000549247.6:n.514G>C
ENST00000553106.5:c.755G>C
NC_000012.12:g.102852902C>G
CM000674.2:g.102852902C>G
NC_000012.11:g.103246680C>G
CM000674.1:g.103246680C>G
NC_000012.10:g.101770810C>G
NG_008690.1:g.69701G>C
NG_008690.2:g.110509G>C

Likely Pathogenic

Met criteria codes 5
PP3 PM2 PM5 PM3 PP4_Moderate

Evidence Links 2

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
The c.755G>C (p.Arg252Pro) variant in PAH has been reported in multiple individuals with PKU (BH4 deficiency excluded, PMID: 21307867). This variant is absent in population databases. This variant was detected in trans with pathogenic variant p.Arg243Gln (PMID: 29316886). Computational evidence supports a deleterious effect. Other missense variants at the p.Arg252 amino acid are pathogenic (p.Arg252Gln/Trp/Gly). In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4_Moderate, PM2, PM3, PM5, PP3.
Met criteria codes
PP3
Predicted deleterious in SIFT, PolyPhen2, MutationTaster. REVEL=0.966
PM2
Absent from controls in ExAC, gnomAD, 1000 Genomes, or ESP
PM5
p.Arg252Gln/Trp/Gly pathogenic
PM3
Detected in trans with p.Arg243Gln (P 10 submitters) variable sites in patient genes were aligned with the corresponding sites from the respective parents. PMID: 29316886

PP4_Moderate
PMID 21307867: 5 alleles of p.Arg252Pro in a cohort of Japanese PKU patients. Serum phenylalanine level higher than 0.18mM. analysis of dihydropteridine reductase activity in red blood cells, biopterin loading test and/or pteridine analysis in urine.

Approved on: 2020-03-15
Published on: 2020-03-15
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.